CoChat

Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC. Improvement in some histological features, but not in histological stage, has been reported after 2 years of UDCA therapy. Thus, longer follow–up may be necessary to determine whether UDCA has a favorable effect on histological stage of disease and progression to cirrhosis. Our aim was to determine the long–term effects of UDCA therapy on histological stage and progression to cirrhosis in patients with PBC. Sixteen unselected patients with noncirrhotic PBC who had been on long–term UDCA therapy (13–15 mg/kg/d) for 6.6 ± 0.4 years (range, 5–9 years) were identified and their histological finding during treatment compared with that of 51 noncirrhotic patients with PBC who had received ineffective therapy (d–penicillamine [DPCA] or placebo) for 5.6 ± 0.07 years (range, 5–8 years). Histological stage was determined using the Ludwig classification. The rate of progression to cirrhosis (stage 4) was significantly less in the UDCA group than in the control group (13% vs. 49%P= .009). Although the overall rate of progression of histological stage was less in the UDCA group than in the control group (50% vs. 71%), this difference was not significant (P= .1). A marked improvement in liver biochemistries and Mayo risk score was noted in all patients during UDCA therapy; however, this improvement was not significantly different between patients who progressed and those who did not. In conclusion, long–term UDCA therapy appeared to delay the development of cirrhosis in PBC.

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.510290301

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 7

  1. Combes, 1995, Hepatology, 22, 759
  2. Emmond, 1996, Hepatology, 24, 168a
  3. Dickson, 1989, 10 Hepatology, 97, 1
  4. Kilmurry, 1996, Hepatology, 23, 1148
  5. Batts, 1996, Am J Gastroenterol, 91, 2314
  6. Lindor, 1995, Hepatology, 22, 1158
  7. Kaplan, 1987, Adv Inten Med, 32, 359

Cited by

See all 235

Metadata

Authors
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D.
Affiliations
Mayo Clinic (US)
Corresponding author
Lindor, Keith D.
Venue
Hepatology
Published
1999-03
Volume
29
Issue
3
Pages
644-647
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1993958712
Cited by
234
References
24
Citations by year
2026: 6 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 10 · 2021: 2 · 2020: 5 · 2019: 11 · 2018: 15 · 2017: 12 · 2016: 7 · 2015: 12 · 2014: 7 · 2013: 7 · 2012: 10
FWCI
7.55
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6028 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
primary biliary cirrhosis, ursodeoxycholic acid, histological progression, long-term treatment, Ludwig classification, D-penicillamine, Mayo risk score, cholestatic liver disease, liver histopathology
MeSH terms
Adult, Aged, Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Middle Aged, Penicillamine, Time Factors, Ursodeoxycholic Acid, Treatment Outcome, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.